Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)

The application of lipid nanoparticles (LNPs) as a non-viral delivery system for advanced therapies, in conjunction with RNA-based medicines, is set to revolutionize the field. David McCall, Senior Editor, BioInsights, speaks to Adrian Bot, Chief Scientific Officer and Executive Vice President of R&D, Capstan Therapeutics, about the potential of these tools to drive the burgeoning in vivo cell therapy space in particular, and the broader gene medicine field in general.

Please enter your email to access content Read now